|Date||Transaction||Number of serie B||Share capital||Quota-
|Total invested capital (SEK)|
|5 Apr 17||Formation||500||50,000||1.00||1.00||50,000|
|29 May 17||Share issue||500||50,000||1.00||1.00||50,000|
|31 Dec 17||Conditional shareholder contribution*||-||-||-||-||1,996,622|
|25 Apr 18||Bond issue||-||400,000||1.00||-||-|
|27 Apr 18||Split||2,999,000||-||0.17||-||-|
|19 Oct 18||Share issue||3,000,000||500,000||0.17||5.26||15,776,962|
|14 Jan 20||Share issue||1,389,385||231,564||0.17||10.00||13,893,850|
|6 Jul 20||Share issue||2,216,815||369,469||0.17||17.50||38,794,263|
|15 Jun 21||Share issue (LTI 2018/21)||200,000||33,334||0.17||11.00||2,200,000|
|21 Dec 21||Share issue||1,199,856||199,976||0.17||11.00||13,198,416|
* Inhalation Sciences Sweden AB did in 2017 provide conditional shareholder contributions amounting to 1 996 622 SEK (cash 0.3 mSEK and reverse loans arising in connection with the acquisition of intangible assets by the parent company converted to shareholder contributions amounting to approximately 1.7 mSEK).
Additional 2 800 086 shares were issued on January 18, 2022 as a final part of the share issue initiated in December 2021. The total number of shares in the company after the completion of the share issue amounts to 13 806 142.